Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

This study has been terminated.
(Novartis is ending their research program for Nilotinib in GIST.)
Sponsor:
Collaborator:
Novartis
Information provided by:
Fox Chase Cancer Center
ClinicalTrials.gov Identifier:
NCT01089595
First received: January 28, 2010
Last updated: March 8, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2012
  Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)